Company Encyclopedia
View More
name
Terumo Corporation
4543.JP
News
View More

Terumo Corporation completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders.

Terumo Corporation has completed the acquisition of a 99.5% stake in OrganOx Limited for $1.5 billion, making it a wholly owned subsidiary. The deal, finalized on October 30, 2025, was funded through cash and borrowings. OrganOx reported total revenue of $69.14 million and EBIT of $9.01 million for the year ending December 31, 2024. The transaction was advised by Perella Weinberg Partners and Piper Sandler, with legal counsel from Latham & Watkins.

marketscreener·
4543
0.00%
marketscreener·
4543
0.00%

Orchestra BioMed Secures $30 Million Strategic Agreement With Terumo for Virtue SAB Rights

Orchestra BioMed Holdings Inc. has entered into a $30 million strategic agreement with Terumo Corporation for the Virtue Sirolimus AngioInfusion Balloon (SAB) aimed at treating coronary artery disease. The deal includes a $10 million upfront payment and a $20 million investment in non-voting preferred stock. Terumo gains a right of first refusal for the global coronary indication of Virtue SAB, while Orchestra BioMed retains all development and distribution rights. The right of first refusal will last until 90 days after the primary endpoint data from the Virtue Trial is disclosed.

Reuters·
US
TRUMY
+1.54%
4543
0.00%
Reuters·
US
TRUMY
+1.54%
4543
0.00%

Terumo Corporation and CSL Plasma Complete Nationwide Rollout of Rika Plasma Donation System Across Over 300 U.S. Centers

Terumo Corporation, through its subsidiary, has completed the nationwide rollout of the Rika Plasma Donation System in partnership with CSL Plasma. This system enhances automation and donor comfort at over 300 centers in the U.S., reducing donation times to under 35 minutes. The initiative aims to increase plasma supply and improve access to plasma-derived therapies for patients with severe hemophilia and rare diseases.

Reuters·
4543
0.00%
Reuters·
4543
0.00%

Terumo (TSE:4543) Could Be A Buy For Its Upcoming Dividend

Terumo Corporation (TSE:4543) is set to trade ex-dividend in three days, with a dividend payment of JP¥15.00 per share scheduled for December 3rd. The company has a trailing yield of approximately 1.2% and paid out 31% of its profit and free cash flow in dividends last year, indicating sustainability. Terumo has shown steady earnings growth of 8.3% over the past five years and a 15% average annual dividend growth over the last decade. This combination suggests potential for future dividend increases, making it an attractive option for investors.

Simplywall·
4543
0.00%
US
TRUMY
+1.54%
Simplywall·
4543
0.00%
US
TRUMY
+1.54%

Terumo's (TSE:4543) Upcoming Dividend Will Be Larger Than Last Year's

Terumo Corporation (TSE:4543) has announced an increased dividend of ¥15.00, payable on December 3rd, matching the industry average yield of 1.1%. The company has a strong track record of stable dividends, with a CAGR of approximately 15% since 2015. With projected EPS growth of 10.7% next year and a comfortable payout ratio of 33%, the dividend appears sustainable. Terumo's consistent earnings growth and reliable dividend payments make it an attractive option for income investors.

Simplywall·
4543
0.00%
US
TRUMY
+1.54%
Simplywall·
4543
0.00%
US
TRUMY
+1.54%